De Novo Pharmaceuticals announces a Drug Discovery Partnership agreement with Achaogen
De Novo Pharmaceuticals Ltd. announced today that it has entered into a drug discovery partnership agreement with Achaogen whereby De Novo will apply its novel molecular structure generating drug discovery platform targeting pathogenic bacteria. Financial terms of the agreement were not disclosed.
"We are very pleased to be working with Achaogen- a leader in the fight against drug-resistant bacteria," said Philip Dean, Ph.D., CSO at De Novo. "Using SkelGen, we will be designing for Achaogen new chemical classes of inhibitors focused on an important drug-resistant bacterial target", he added.
"We are pleased to be working with De Novo to expand our lead optimization program, and to help us develop cutting-edge therapeutics that will speed us towards our goal of providing therapies to treat unmet clinical needs caused by multi-drug resistant bacterial infections," said Phillip Patten, Ph.D., Senior Vice President, Biology at Achaogen.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.